Definium Therapeutics, Inc. DFTX 深 沪
等待开盘 08-17 09:30:00 美东时间
42.63
-1.270
-2.89%
华盛通- 最 高43.74
- 今 开43.00
- 成交量 170.55万股
- 最 低 42.01
- 昨 收 43.90
- 总市值 572.81万
- 52周最高 49.70
- 市盈率 静 --
- 换手率 1.27%
- 52周最低 8.70
- 委 比 -31.70%
- 总股本 0.00亿
- 历史最高 86.55
- 量 比 0.46
- 振 幅 3.94%
- 历史最低 2.20
- 每 手 1
- 风险率 10.95%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Maxim Group Maintains Buy on Definium Therapeutics, Raises Price Target to $55
Maxim Group maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $50 to $55.
08-15 04:12
美股大行评级 | 潜在涨幅544.53%！Scynexis获古根海姆升目标价至33美元，维持"买入"评级
今日重点评级关注：古根海姆：维持Scynexis"买入"评级，目标价从24美元升至33美元；韦德布什：维持Kura Oncology"跑赢大市"评级，目标价从36美元升至38美元
08-14 11:51
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
Definium Therapeutics Says Unprecedented Efficacy From Anxiety Study 'Raises the Bar'
Late-stage clinical biopharmaceutical firm Definium Therapeutics, Inc. (NASDAQ:DFTX) has announced highly encouraging topline data from its Voyage trial. The Phase 3 study evaluated the efficacy of DT120 (lysergide) Orally Disintegrating Tablet (ODT) 100 µg in adults suffering from generalized anxie...
08-12 22:23
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
Piper Sandler Reiterates Overweight on Definium Therapeutics, Raises Price Target to $75
Piper Sandler analyst David Amsellem reiterates Definium Therapeutics (NASDAQ:DFTX) with a Overweight and raises the price target from $73 to $75.
08-08 01:02
美股大行评级 | ITG、Bending Spoons获多家大行首予买入评级；瑞银下调微软目标价从510美元降至480美元
今日重点评级关注：BTIG：上调Outlook Therapeutics"买入"评级，目标价4美元；TD Cowen：维持Nakamoto"买入"评级，目标价从1美元升至17美元
07-28 11:34
美股大行评级 | 最高120美元！大小摩等7家大行集体上调英特尔目标价；汇丰首予SpaceX"持有"评级，目标价115美元
今日重点评级关注：HC Wainwright & Co.：维持居里"买入"评级，目标价从17美元升至43美元；花旗：维持Klaviyo"买入"评级，目标价从31美元升至34美元
07-27 14:02
Piper Sandler Reiterates Overweight on Definium Therapeutics, Raises Price Target to $73
Piper Sandler analyst David Amsellem reiterates Definium Therapeutics (NASDAQ:DFTX) with a Overweight and raises the price target from $48 to $73.
07-24 23:01
Why Is GH Research Stock Trading Higher on Thursday?
GH Research PLC (NASDAQ:GHRS) and Definium Therapeutics Inc. (NASDAQ:DFTX) stocks are trading higher in response to Eli Lilly and Co. (NYSE:LLY) agreeing to acquire AtaiBeckley Inc. (NASDAQ:ATAI) in a deal valued at up to $3.80 billion. Bloomberg was the first to report the deal. AtaiBeckley is one ...
07-17 00:36
